Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.53 |
| ▸ | HPGDS | O60760 | 12/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159251 | 0.86 | KDM1A (0.60) | KDM1AHPGDSRCOR1MAOA | |
| SCHEMBL17158999 | 0.83 | MAOA (0.66) | KDM1AHPGDSRCOR1MAOA | |
| SCHEMBL17159122 | 0.83 | KDM1A (0.66) | KDM1AHPGDSRCOR1MAOA | |
| SCHEMBL17159150 | 0.83 | KDM1A (0.68) | KDM1ARCOR1MAOA | |
| SCHEMBL17159387 | 0.81 | MAOA (0.57) | KDM1AHPGDSRCOR1MAOA | |
| SCHEMBL17159253 | 0.80 | MAOB (0.69) | KDM1ARCOR1MAOA | |
| SCHEMBL21471771 | 0.80 | KDM1A (0.52) | KDM1ARCOR1MAOA | |
| SCHEMBL17158782 | 0.79 | KDM1A (0.73) | KDM1ARCOR1MAOA | |
| SCHEMBL17159195 | 0.79 | KDM1A (0.73) | KDM1ARCOR1MAOA | |
| Hydrochloric Acid SCHEMBL17158677 | 0.78 | KDM1A (0.72) | KDM1ARCOR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM1A 1/4885HPGDS 2784/4885ROCK2 1405/4885 |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | KDM1A 1/4885HPGDS 2784/4885ROCK2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.